Logo
x

Search

Subscribe Now

REGENERON

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent (Dupilumab) to Treat Chronic Spontaneous Urticaria (CSU)

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent (Dupilumab) to Treat Chronic Spontaneous Urticaria (CSU)

  • November 15, 2024
Regeneron’s Ordspono (Odronextamab) Receives the EC’s Approval to Treat R/R Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron’s Ordspono (Odronextamab) Receives the EC’s Approval to Treat R/R Follicular Lymphoma and Diffuse Large B-cell Lymphoma

  • August 26, 2024
Regeneron Showcases Updated on BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)

Regeneron Showcases Updated on BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)

  • August 21, 2024
Regeneron and Sanofi Report the EC’s Approval of Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)

Regeneron and Sanofi Report the EC’s Approval of Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)

  • July 3, 2024
Regeneron’s Ordspono Gains the CHMP’s Positive Opinion to Treat r/r Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Regeneron’s Ordspono Gains the CHMP’s Positive Opinion to Treat r/r Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLB...

  • June 28, 2024
Regeneron Showcases Updated P-I/II (LINKER-MM1) Study Data of Linvoseltamab for Treating R/R Multiple Myeloma at EHA 2024

Regeneron Showcases Updated P-I/II (LINKER-MM1) Study Data of Linvoseltamab for Treating R/R Multiple Myeloma at EHA 2024

  • June 17, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.